Page 4 - Gsk

Drug major GSK sold off up to 10 tail-end brands in FY19 including Celin

According to the firm's FY19 annual report, it fetched Rs 5 crore during the year from the sale of brands

GSK to invest Rs 1,000 cr in Karnataka for new plant

Factory to commence production from 2018

GSK files potential $1 billion shingles vaccine for US approval

Shingrix is viewed by analysts as among the British drugmaker most promising experimental products

GSK puts Mumbai land on the block again

The land parcel is valued between Rs 1,400 crore and Rs 1,800 crore

GSK Consumer valuation unsustainable

Revenues declined; competition led to higher ad spends and impacted profits